Head and Neck Cancer Drugs Market To Reach $2.58 Billion By 2029 says Visiongain report

20 December 2019
Pharma

Visiongain’s new report the Head and Neck Cancer Drugs Market Report 2019-2029: Forecasts by Treatment (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy), by Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), by Distribution Channel (Hospitals, Online Providers, Drug stores & retail pharmacies), plus analysis of leading companies operating in the global head and neck cancer drugs market.

Increasing global geriatric population, growing prevalence of neck and head cancer, and increasing tobacco and alcohol consumption is expected to increase global head and neck cancer drugs market over the projected period. In 2019, the global head and neck cancer drugs market was valued at $963 million and is expected to reach $2.58 billion by 2029 at a CAGR of 10.3% over the projected period.

According to the World Health Organization, tobacco kills more than 8 million people each year. More than 7 million of those deaths are the result of direct tobacco use while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. Tobacco consumption is ranked as the leading cause of illness, death, and impoverishment. Increasing tobacco consumption has increased the prevalence of head and neck cancer over the past few years and the trend is expected to continue over the course of time. 

Increasing geriatric population in developed as well as developing economies are expected to prone more towards chronic diseases, which in turn is expected to drive the head and neck cancer drugs market. Some identified disruptive drugs are Opdivo, Keytruda, Imfinzi, Bavencio, Yervoy, Tremelimumab, Buparlisib, and Epacadostat.

List of head and neck cancer drugs providers identified in this report are  Bristol-Myers Squibb, Merck, Sanofi, Eli Lilly, AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Limited.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

Read

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

Read

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

Read

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever